Flagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity

Recent News

April 28, 2025

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

Lead development candidate, AMP-410, is activated only by VEGF signals in tumors and binds to the 4-1BB receptor on immune cells to drive immune response and anti-tumor activity

March 19, 2025

Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company; Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025; Second discovery partnership in obesity initiated